Oppenheimer upgrades Intuitive Surgical to Outperform on AI and robotic surgery growth
The upgrade contrasts with recent downgrades from HSBC, though Wall Street consensus remains a Strong Buy with a mean target of $480.93.
Oppenheimer has upgraded Intuitive Surgical from a Perform rating to Outperform, assigning a $500 price target that implies a 24.6 per cent upside from current levels. The firm highlighted the company’s dominant position in robotic surgery and its development of artificial intelligence capabilities as primary catalysts for the move.
Intuitive Surgical’s second-quarter results provided a robust foundation for the upgrade. Revenue rose 18.5 per cent year-on-year to $2.89 billion, surpassing the $2.82 billion consensus estimate. Non-GAAP net income per share increased 27.9 per cent to $2.80, beating the $2.50 expectation, while non-GAAP gross profit margins expanded to 70 per cent.
The medical technology company placed 468 da Vinci surgical systems and 55 Ion endoluminal systems during the quarter. Global combined procedures for the da Vinci and Ion platforms grew approximately 16 per cent year-on-year, with da Vinci procedures rising roughly 15 per cent and Ion procedures surging around 36 per cent.
Oppenheimer analysts noted that Intuitive is building an AI capability stack that leverages real-world surgical data to create advanced vision-language and reasoning models. These tools are designed to assist medical personnel in achieving better outcomes by answering complex surgical questions, reinforcing the company’s leadership despite increasing market competition.
Looking ahead, Intuitive expects global da Vinci procedure growth of approximately 13.5 per cent to 15.5 per cent for the current year, with non-GAAP gross profit margins projected between 68 per cent and 69 per cent. The company’s forward-adjusted price-to-earnings ratio stands at 37.18 times, significantly higher than the industry average of 19.60 times.
While the upgrade marks a positive shift, it contrasts with recent downgrades from HSBC, which lowered its rating to Hold in July with a $391 price target. JPMorgan and Piper Sandler also adjusted their targets downwards in recent months, though both maintained bullish stances on the stock.
Despite these adjustments, broader Wall Street sentiment remains overwhelmingly positive. Of the 31 analysts covering the stock, 22 rate it a Strong Buy, two a Moderate Buy, six a Hold, and one a Strong Sell. The consensus price target sits at $480.93, implying a 19.85 per cent upside, with the highest Street target reaching $685.
